Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
Statistics in Medicine|June 3, 2015
A non-parametric approach to estimate the total deviation index for non-normal dataSara Perez-Jaume, Josep L CarrascoPediatric Blood & Cancer|August 1, 2024
Radiation recall reaction induced by gemcitabine/docetaxel in children: A retrospective study on risk factors and outcomesCristina Larrosa, Soraya Mico, Mónica Ramos, et al.Journal of Pediatric Hematology/Oncology|October 2, 2023
Vitamin D Status in Children With High-risk NeuroblastomaAna Carolina Izurieta-Pacheco, Ana Sangrós-Gimenez, Esther Martínez-Garcia, et al.Pediatric Blood & Cancer|May 22, 2021
Naxitamab combined with granulocyte-macrophage colony-stimulating factor as consolidation for high-risk neuroblastoma patients in complete remissionJaume Mora, Alicia Castañeda, Maite Gorostegui, et al.Frontiers in Pharmacology|December 16, 2020
The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive StudiesJaume Mora, Alicia Castañeda, Miguel A Flores, et al.Frontiers in Oncology|May 22, 2023
Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamabAmalia Varo, Alicia Castañeda, Saray Chamorro, et al.Heliyon|April 22, 2024
DRI Triton SS-OCT applied to detect choroidal nodules in paediatric patients affected by NF1Carlos Fresno Cañada, Joan Gispets Parcerisas, Cristina Del Prado Sánchez, et al.British Journal of Haematology|March 23, 2023
A miRNA signature related to stemness identifies high-risk patients in paediatric acute myeloid leukaemiaElena Esperanza-Cebollada, Soledad Gómez-González, Sara Perez-Jaume, et al.Cancers|May 11, 2024
Management of High-Risk Neuroblastoma with Soft-Tissue-Only Disease in the Era of Anti-GD2 ImmunotherapyMaite Gorostegui, Juan Pablo Muñoz, Sara Perez-Jaume, et al.Cancers|May 13, 2023
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome ReportJaume Mora, Alicia Castañeda, Maite Gorostegui, et al.Pageof 3